Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.

Viral epidemic infections due to influenza, or coronaviruses, particularly influenza A and SARS-CoV-1 and -2 virus cause significant morbidity and mortality. The significant mutation rate of this group of viruses renders existing vaccines or antiviral drugs often useless, creating a need for broad acting, viral DNA or RNA sequence independent antiviral drugs. This invention describes the repurposing of methylene blue and riboflavin, two FDA approved drugs with an excellent safety profile. Using a virus neutralization assay of H1N1 Influenza A and SARS-CoV-2, the significant viricidal activity of both drugs at pharmacological dose and under physiological conditions is demonstrated. In vivo prophylactic and therapeutic use of the drugs for anti-viral application in an animal model is described.

Viral epidemic infections due to influenza, or coronaviruses, particularly influenza A and SARS-CoV-1 and -2 virus cause significant morbidity and mortality. The significant mutation rate of this group of viruses renders existing vaccines or antiviral drugs often useless, creating a need for broad acting, viral DNA or RNA sequence independent antiviral drugs. This invention describes the repurposing of methylene blue and riboflavin, two FDA approved drugs with an excellent safety profile. Using a virus neutralization assay of H1N1 Influenza A and SARS-CoV-2, the significant viricidal activity of both drugs at pharmacological dose and under physiological conditions is demonstrated. In vivo prophylactic and therapeutic use of the drugs for anti-viral application in an animal model is described.

Viral epidemic infections due to influenza, or coronaviruses, particularly influenza A and SARS-CoV-1 and -2 virus cause significant morbidity and mortality. The significant mutation rate of this group of viruses renders existing vaccines or antiviral drugs often useless, creating a need for broad acting, viral DNA or RNA sequence independent antiviral drugs. This invention describes the repurposing of methylene blue and riboflavin, two FDA approved drugs with an excellent safety profile. Using a virus neutralization assay of H1N1 Influenza A and SARS-CoV-2, the significant viricidal activity of both drugs at pharmacological dose and under physiological conditions is demonstrated. In vivo prophylactic and therapeutic use of the drugs for anti-viral application in an animal model is described.

The invention provides compounds having the general formula I: ##STR00001##
and pharmaceutically acceptable salts thereof, wherein the variables R.sup.1, R.sup.2, R.sup.3, R.sup.4, subscript m and n, have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

The invention provides compounds having the general formula I: ##STR00001##
and pharmaceutically acceptable salts thereof, wherein the variables R.sup.1, R.sup.2, R.sup.3, R.sup.4, subscript m and n, have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.

The invention provides compositions, formulations, and methods for treatment of malignancies via activation of an inflammatory response in the subject. Such compositions, formulations, and methods for are preferably used in conjunction with other therapies for the treatment and/or management of malignancies, e.g., chemotherapy and/or radiation. The invention also provides methods of monitoring immune activation in subjects with malignancies.

The invention provides compositions, formulations, and methods for treatment of malignancies via activation of an inflammatory response in the subject. Such compositions, formulations, and methods for are preferably used in conjunction with other therapies for the treatment and/or management of malignancies, e.g., chemotherapy and/or radiation. The invention also provides methods of monitoring immune activation in subjects with malignancies.

The present disclosure relates to a process for preparing a pharmaceutical formulation, said process comprises: i) blending chlorpromazine hydrochloride and microcrystalline cellulose under a first set of pre-determined conditions to obtain a first mixture; ii) blending lactose monohydrate with first mixture under a second set of pre-determined conditions to obtain a second mixture; iii) blending pre-gelatinized starch, colloidal silicon dioxide and magnesium stearate with second mixture under a third set of pre-determined conditions to obtain a third mixture; iv) screening the third mixture through #40 Mesh and dry blending under a fourth set of pre-determined conditions to obtain a fourth mixture; and v) directly compressing the fourth mixture to obtain the pharmaceutical formulation.

The present disclosure relates to a process for preparing a pharmaceutical formulation, said process comprises: i) blending chlorpromazine hydrochloride and microcrystalline cellulose under a first set of pre-determined conditions to obtain a first mixture; ii) blending lactose monohydrate with first mixture under a second set of pre-determined conditions to obtain a second mixture; iii) blending pre-gelatinized starch, colloidal silicon dioxide and magnesium stearate with second mixture under a third set of pre-determined conditions to obtain a third mixture; iv) screening the third mixture through #40 Mesh and dry blending under a fourth set of pre-determined conditions to obtain a fourth mixture; and v) directly compressing the fourth mixture to obtain the pharmaceutical formulation.